Press release
United Therapeutics Corporation Reports Third Quarter 2024 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today
About this update from United Therapeutics Corporation
[{"type":"text","content":" SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--\nUnited Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2024. Total revenues in the third quarter of 2024 grew 23 percent year-over-year to $748.9 million, compared to $609.4 million in the third quarter of 2023.\n\n\"I’m proud of the close to 1,300 Unitherians who have contributed to yet another record revenue quarter and reaching a $3 billion annual revenue run rate in the third quarter,\" said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. \"On top of our stellar revenue performance, 2025 marks the start of a multi-year cascade of clinical data reads and regulatory events that should continue to propel our growth through the balance of the decade and beyond, with data expected for the TETON studies in idiopathic pulmonary fibrosis and ADVANCE OUTCOMES in pulmonary arterial hypertension; data from the miroliverELAP phase 1 study now underway for acute liver failure; and, importantly, the launch of our UKidney human clinical program for which we expect to file an investigational new drug application shortly.\"\n\nMichael Benkowitz, President and Chief Operating Officer of United Therapeutics, added, \"Our team’s efforts have once again translated into outstanding financial results, achieving record revenue for a sixth straight quarter that underscores the increasing demand for our innovative products serving pulmonary hypertension and high-risk neuroblastoma patients. Tyvaso remains our biggest near-term growth driver, and we are encouraged by the underlying dynamics driving its continued uptake in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.\"\n\nThird Quarter 2024 Financial Results\n\nKey financial highlights include (dollars in millions, except per share data):\n\n\n\n \n\n\n\nThree Months Ended\nSeptember 30,\n\n\n\n \n\n\n\nDollar\nChange\n\n\n\n \n\n\n\nPercentage\nChange\n\n\n\n\n\n \n\n\n\n2024\n\n\n\n \n\n\n\n2023\n\n\n\n \n\n\n\n \n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\nTotal revenues\n\n\n\n$\n\n\n\n748.9\n\n\n\n \n\n\n\n$\n\n\n\n609.4\n\n\n\n \n\n\n\n$\n\n\n\n139.5\n\n\n\n \n\n\n\n23 %\n\n\n\n\n\nNet income\...